Novartis: Arthritis trials

The registry lists 16 Arthritis studies with Novartis as lead sponsor. 1 are open to participants now and 12 have results posted.

Phase 1 2Phase 2 6Phase 3 8Phase 4 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A 52-Week Study Evaluating the Efficacy and Safety of Arumakimig (MAS825) in Participants With VEXAS Followed by Open-Label Extension (OLE) PeriodRecruitingNCT07748624Phase 2
• Study of Efficacy, Safety, and Tolerability of LNA043 in Patients With Knee OsteoarthritisTerminatedNCT04864392Phase 2Results posted
• A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's SyndromeTerminatedNCT04035668Phase 2Results posted
• Secukinumab Safety and Efficacy in Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-related Arthritis (ERA)CompletedNCT03031782Phase 3Results posted
• Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to PlaceboCompletedNCT02798211Phase 4Results posted
• 1 Year of Treatment With Canakinumab in Behçet's Disease Patients With Neurologic or Vascular InvolvementCompletedNCT02756650Phase 2Results posted
• Study of Power Doppler Ultrasound (PDUS) to Measure Response of Secukinumab Treatment in Patients With Active Psoriatic Arthritis (PsA)CompletedNCT02662985Phase 3Results posted
• Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic ArthritisCompletedNCT02404350Phase 3Results posted
• Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis PatientsCompletedNCT01431638Phase 3Results posted
• Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis PatientsCompletedNCT01356602Phase 3Results posted
• An Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Active Systemic Manifestations Manifestations and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever.CompletedNCT00891046Phase 3Results posted
• Flare Prevention Study of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)CompletedNCT00889863Phase 3Results posted
• Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA)TerminatedNCT00886769Phase 3Results posted
• Safety and Efficacy of BFH772 in Psoriasis PatientsCompletedNCT00987870Phase 1/2
• Efficacy and Safety of Subcutaneous Versus Intravenous ACZ885 in Adult Patients With Established Rheumatoid ArthritisTerminatedNCT00505089Phase 1/2
• Efficacy and Safety of Lumiracoxib 400 mg Once Daily in Acute Flares of GoutCompletedNCT00170781Phase 4